Phillip J. Koo, MD, presented “Advances in Imaging: a Radiologist’s Perspective” virtually during the 21st Annual Future Directions in Urology Symposium in August 2020.
How to cite: Koo, Phillip J. “Advances in Imaging: a Radiologist’s Perspective” August 10th, 2020. Accessed Jul 2024. https://grandroundsinurology.com/advances-in-imaging-a-radiologists-perspective/
Summary:
Phillip J. Koo, MD, Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center, discusses current applications and potential future uses of PSMA PET/CT for imaging and treating prostate cancer. Dr. Koo notes that data from studies like ProPSMA clearly show that PSMA PET/CT is the most accurate and best diagnostic test available for prostate cancer. Access remains a problem however, as 68Ga-PSMA-11 is only currently available at two institutions in the United States. This will hopefully change soon, as companies are working to make cold kits for 68Ga-PSMA-11 widely available as well as to develop alternative imaging agents. As its availability increases, many questions remain about how PSMA PET/CT’s imaging capabilities can aid in treatment of metastatic and oligometastatic disease, and Dr. Koo concludes his discussion by observing that researchers have only just scratched the surface of PSMA’s value.
For more on imaging for prostate cancer, visit our learning center.
About The 2020 Virtual Future Directions in Urology Symposium
The Future Directions in Urology Symposium was founded 21 years ago to reflect on the current state of the urology community and predict trends in the treatment of urology conditions in the following 5-10 years. This conference brings together experts in the field, including urologists, medical oncologists, radiation oncologists, family practice doctors, researchers, and industry leaders to review current trends and prospects. Dr. Koo presented this lecture during this year’s virtual conference in August 2020.
ABOUT THE AUTHOR
Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian and his radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System in Philadelphia, Pennsylvania. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM). His academic interests have focused on PET imaging in prostate cancer, response to novel therapies using PET, and data-driven motion correction. He has lectured nationally and internationally on topics related to imaging and radiopharmaceutical based therapies in prostate cancer. In 2022, Dr. Koo was the recipient of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Presidential Distinguished Service Award.
